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The existence of natural antimicrobial sub-
stances, contributing to the mechanisms of 
host defenses, has been recognized since 
the late nineteenth century. In 1963, the 
in vitro antibacterial activity of leukocyte 
extracts was attributed to basic proteins. 
Since the late 1980s, cationic peptides with 
antimicrobial properties have been subse-
quently identified in other host cells and 
tissues and in virtually every living species 
(Lehrer, 2004). The properties of these 
“Nature’s antibiotics” and their multiple 
functions in host defenses of multicellular 
organisms support the rationale of devel-
oping entirely novel peptide-based thera-
peutics harnessing the effector mechanisms 
of innate immunity (Hancock and Sahl, 
2006). The term antimicrobial peptides 
covers different forms of natural macro-
molecules; ribosomally synthesized and 
non-post-translationally modified innate 
immunity peptides, or their synthetic ana-
logs, are predominantly considered here. 
Their antimicrobial and immunomodu-
latory activities will not be dissociated in 
general and they will be indistinctively 
described as (cationic) antimicrobial or 
host defense peptides.
The main assets of innate immunity 
peptides originate from their primary activ-
ity essentially directed at a universal non-
protein target, the bacterial membrane, 
reinforced by a polypharmacology which 
includes multiple immunomodulatory and 
anti-inflammatory activities (Zasloff, 2002; 
Finlay and Hancock, 2004). Other distinc-
tive and attractive properties in a clinical 
context comprise their low susceptibility 
to classical mechanisms of drug resistance, 
associated with a low propensity to select 
resistant mutants, their ability to reduce 
both biofilm and planktonic bacterial 
counts and to interact with dividing and 
non-dividing cells by generally targeting 
a conserved structure which is independ-
ent of the proliferative status of the cells 
(Peschel and Sahl, 2006; Chen et al., 2011; 
Fjell et al., 2012). Although some mecha-
nisms of bacterial resistance to antimicro-
bial peptides have been identified, their 
emergence occurs at significantly lower 
frequencies than for traditional antibiot-
ics (Peschel and Sahl, 2006). Furthermore, 
host defense peptides can also act synergis-
tically with these classical antibiotic agents 
(Giacometti et al., 2000).
Innate immunity peptides are therefore 
a prospective source of antibiotic can-
didates with extended clinical lifetimes. 
They have not been approved for clinical 
use to date, but have progressed toward 
commercial development through recent 
technological advances. About 1,200 to 
1,700 antimicrobial peptide sequences have 
been identified and/or predicted to date. 
Approximately 15 different peptide-based 
therapeutic agents are currently in clinical 
trials for anti-infective and/or anti-inflam-
matory indications, generally limited to 
topical administration (Fjell et al., 2012; 
Yount and Yeaman, 2012). The challenges 
traditionally associated with the clinical 
development of host defense peptide candi-
dates for systemic therapies require notably 
solutions addressing the question of pos-
sible toxicity. Owing to their rapid meta-
bolic degradation and/or excretion, high 
doses of these peptides might be required 
to maintain therapeutic levels in vivo. This 
may correlate with an improper margin of 
safety, despite their selectivity for bacterial 
over mammalian cells (Zasloff, 2002). In 
addition, the issue of potential immuno-
genicity should be considered (Mader and 
Hoskin, 2006). Other concerns may be 
raised, either inherent to all peptide-based 
drug  candidates, such as low oral bioavail-
abilities and elevated cost of production, 
or specific to host defense peptides, in par-
ticular their complex pharmacology which 
could result in uncontrolled off-target 
toxicity (Pauletti et al., 1997; Hancock and 
Sahl., 2006; Brown et al., 2007).
Peptide therapeutics are capturing an 
increasing fraction of the global pharmaceu-
tical pipeline. Advances in peptide modifica-
tion, formulation, and delivery technologies 
can overcome some of their pharmacoki-
netic, bioavailability, and toxicity short-
comings and likewise have been applied to 
innate immunity peptides. The latter have 
been modified by either optimizing the 
length and content of their sequences, to 
increase their selective antibacterial activity, 
or by conversion into peptidomimetics, to 
improve their pharmacokinetic properties. 
In the first case, minimizing the length of 
the sequence and systematically substituting 
each residue with other coded amino acids, 
can yield peptide candidates with improved 
antibacterial activity and/or increased activ-
ity differentials between prokaryotic and 
eukaryotic (generally erythrocytes) cells. 
This work has been performed in parallel 
with structure activity relationship studies 
for the rationale design of therapeutic can-
didates (Fjell et al., 2012). It focused on the 
direct antibacterial activity of some selected 
candidates, but immunomodulatory pep-
tides devoid of in vitro antimicrobial activ-
ity have also been optimized (Hancock 
et al., 2012). In the second case, peptido-
mimetics, structures departing from the 
traditional peptide backbone and/or stere-
ochemistry but reproducing the biological 
activity of the parent sequence, have been 
generated as candidates resistant to prote-
olysis. They include sequences assembled 
from non-natural amino acids (e.g., D- or 
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β-amino acids or proteinogenic amino acid 
analogs with increased hydrophobicity), 
N- or C-terminally modified with lipo-
philic chains or groups and also peptoids 
and non-peptide mimetics (e.g., aminos-
teroids or amphiphilic polymers; Brogden 
and Brogden, 2011; Yount and Yeaman, 
2012). Other methods for improving the 
pharmacokinetic properties, preventing 
the immunogenicity and serum protein 
inactivation of biopharmaceuticals, such as 
the pegylation technology, have also been 
implemented (Harris and Chess, 2003; 
Imura et al., 2007).
The issue of unknown toxicology for 
systemically administered innate immunity 
peptides has also been addressed in a num-
ber of these approaches. Alternatively, some 
modified peptides or peptidomimetics may 
retain not only the activity, but also the tox-
icity of the parent peptide. To efficiently and 
reliably control the toxicity of a therapeu-
tic candidate, a selective delivery technol-
ogy can be implemented as an alternative 
method, or in combination with the previ-
ous approaches. These methods can confine 
the activity of innate immunity peptides to 
the sites of infection and generate thereby 
targeted antimicrobial peptides. They con-
sist either of peptide sequences conjugated 
to targeting moieties, modified as inactive 
precursors which can be selectively acti-
vated at a target body site, or loaded in 
drug delivery systems that can be targeted 
to their desired site of action. In the former 
case, the targeting moiety can be an anti-
body directed against a pathogen-specific 
antigen. A host defense peptide sequence 
is in this case conjugated to the sequence 
of an antibody fragment through the pro-
duction of a fusion protein containing or 
not a cleavable linker between the targeting 
and antimicrobial domains (Peschen et al., 
2004; Szynol et al., 2006; Franzman et al., 
2009). The resulting immunoconjugate can, 
for example, confer specific resistance to a 
fungus in transgenic plants or discriminate 
a specific periodontal pathogen from other 
bacteria of the oral commensal flora. The 
targeting moiety can also be another pep-
tide sequence that can bind selectively to a 
specific cell surface receptor of a bacterial 
pathogen, such as a pheromone receptor for 
instance. A targeted antimicrobial candidate 
is then generated as a fusion or synthetic 
peptide comprising the antimicrobial and 
pheromone sequences (Qiu et al., 2003; 
Eckert et al., 2006). These chimeric peptides 
can, for example, discriminate between 
Staphylococcus aureus (MSSA and MRSA 
strains) and Staphylococcus epidermidis or 
Streptococcus pneumoniae and be protective 
in a mouse model of infection with MRSA, 
or selectively eliminate the cariogenic bac-
terium Streptococcus mutans in planktonic 
cultures and multispecies biofilms, without 
affecting closely related non-cariogenic oral 
streptococci.
The generation of targeted antimicrobial 
peptides has also been investigated through 
the conjugation of a classical antibiotic to a 
host defense peptide sequence, to increase 
its selectivity and activity against bacteria 
expressing the target of the conventional 
antibiotic. Vancomycin-peptide conju-
gates of magainin 2 were for example con-
structed by using the copper(I)-catalyzed 
azide-alkyne cyclo-addition (Arnusch et al., 
2012). This approach yields hybrid antibiot-
ics containing 2 different pharmacophores, 
which can capitalize on their dual activity 
to increase their efficiency and delay resist-
ance development, but can also restore 
the activity of the classical agent against 
resistant bacteria (Pokrovskaya and Baasov, 
2010). Another application of these hybrid 
antibiotics is in the generation of antimi-
crobial peptide prodrug candidates, where 
the classical antibiotic acts as a promoiety 
rather than as an active agent (Rautio et al., 
2008). For example, conjugation of a cepha-
losporin to a host defense peptide sequence 
can reversibly modulate one of the activity 
determinants, the net charge, of the parent 
peptide (Desgranges et al., 2012). The latter 
can be selectively released from the conju-
gate by β-lactamase-mediated hydrolysis of 
the cephalosporin’s lactam ring, a reaction 
which constitutes the main mechanism 
of antibiotic resistance in Gram-negative 
pathogens. A prodrug modification has 
been proposed as a promising strategy to 
potentiate the systemic applications of host 
defense peptides and has been frequently 
used to overcome the toxicity of low molec-
ular weight drug candidates, but also of the 
lipopeptide polymyxin E (Hancock, 2001; 
Stella, 2004). Nature also selected a prod-
rug approach to regulate and control the 
activity of some innate immunity peptides 
(Yeaman and Yount, 2007). This natural 
mechanism can be synthetically mimicked 
by generating peptide sequences containing 
three domains, including an oligo-glutamyl 
profragment, a linker cleavable by a target 
disease-associated protease and the parent 
sequence of a host defense peptide assem-
bled from D-amino acids (Desgranges et al., 
2011). Activity and toxicity differentials can 
be achieved between a neutrophil elastase-
dependent propeptide and its parent pep-
tide, although enzymes of bacterial origin 
that have narrow substrate specificities and 
no mammalian homologs might have to be 
targeted for the activation of a propeptide 
systemically administered. Finally, peptide 
prodrugs containing a promoiety yield-
ing itself a pharmacologically active entity 
upon activation, i.e., co-drugs, can target 
an antimicrobial peptide to a site of bacte-
rial infection or colonization while allowing 
the co-delivery of an agent with a comple-
mentary activity. For example, conjuga-
tion through an azo bond of aniline-based 
agents such as 4-aminophenylacetic acid or 
5-aminosalicylic acid, to the N-terminus of 
a peptide requiring a free Nα-amino group, 
can generate co-drug candidates for colonic 
delivery of non-steroidal anti-inflamma-
tory and antibiotic agents (Kennedy et al., 
2011). The metabolic activation of these 
two therapeutic candidates can only be 
performed by azo-reductases, enzymes lim-
ited to anaerobic bacteria only, restricting 
thereby the activity of the peptide to the 
colon. Alternatively, environmentally sen-
sitive antimicrobial peptides, such as pH-
responsive sequences, can inherently have 
their activity confined to a particular body 
site (Li et al., 2010).
Antimicrobial peptides can also be tar-
geted through their loading in nanoparticu-
late systems with selective delivery capacity. 
They include liposomes, including stealth 
liposomes, polymeric structures, including 
hydrogels and dendritic polymers, nano-
spheres, and nanocapsules, carbon nano-
tubes and DNA cages (Urbán et al., 2012). 
Their nanoscale size determines their drug 
loading capacities, but prolongs their circu-
lation times. Their structure can protect the 
cargo from metabolic degradation and limit 
its toxicity by preventing its interaction 
with plasma proteins and host cell surfaces. 
Furthermore, the release of the cargo can be 
environmentally controlled or the surfaces 
of these nano-carriers can be modified with 
targeting moieties to allow their selective 
delivery to specific cells or tissues and even 
through the blood-brain barrier. Some of 
these drug delivery systems (e.g., liposome, 
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protein, and polymer carriers) have already 
been investigated with host defense peptides 
as cargoes (McClanahan et al., 2011; Yount 
and Yeaman, 2012).
Finally, the concern related to the ele-
vated cost of production of these candi-
dates is now moderated by the advances 
in their production methods, such as the 
recombinant expression in heterologous 
microbial systems (Mygind et al., 2005; Li, 
2011). Applicable to the production of pep-
tides assembled from natural amino acids, 
it is also complemented by the solid phase 
synthetic approach which allows the cost-
effective production on a multi-tonne per 
year scale of peptides, but also modified 
peptides and peptidomimetics, that can 
meet the requirements of regulatory agen-
cies (Bray, 2003).
The therapeutic potential of host defense 
peptides can be extended beyond the anti-
infective and anti-inflammatory applica-
tions to cancer therapy. Indeed, innate 
immunity peptides can be active against 
prokaryotic and neoplastic eukaryotic cells, 
according to the high anionic lipid content 
of the bacterial, malignant cells and mito-
chondrial membranes and to structural 
differences between the bacterial or cancer 
cell membranes and the plasma membrane 
of normal eukaryotic cells (Papo and Shai, 
2005; Mader and Hoskin, 2006). Some of the 
approaches developed in the anti-infective 
and anticancer areas to address, separately or 
collectively, the limitations of antimicrobial 
peptides, could address the clinical short-
comings associated with these candidates 
and the optimization and/or combination of 
these approaches, together with the advances 
in production and purification methods, 
could ultimately realize the full therapeutic 
potential of antimicrobial peptides.
Acknowledgments
The author would like to thank Prof. 
Hilary Humphreys, Dr Deirdre Fitzgerald-
Hughes, Dr Timothy Smyth, Dr Stéphane 
Desgranges, Dr Carol Ruddle, Mr Liam 
Burke and Dr David Kennedy for the 
development of the peptide prodrugs and 
co-drugs cited in this manuscript. This 
publication has emanated from research 
conducted with the financial support of 
Science Foundation Ireland (SFI 05/RFP/
CHE0063, 06/RFP/CHO024, and 06/RFP/
CHO024/EC07) and Enterprise Ireland (EI 
PC/2005/164).
RefeRences
Arnusch, C. J., Pieters, R. J., and Breukink, E. (2012). 
Enhanced membrane pore formation through high-
affinity targeted antimicrobial peptides. PLoS ONE 7, 
e39768. doi: 10.1371/journal.pone.0039768
Bray, L. B. (2003). Large-scale manufacture of peptide 
therapeutics by chemical synthesis. Nat. Rev. Drug 
Discov. 2, 587–593.
Brogden, N. K., and Brogden, K. A. (2011). Will new gen-
erations of modified antimicrobial peptides improve 
their potential as pharmaceuticals? Int. J. Antimicrob. 
Agents 38, 217– 225.
Brown, K. L., Cosseau, C., Gardy, J. L., and Hancock, 
R. E. W. (2007). Complexities of targeting innate 
immunity to treat infection. Trends Immunol. 28, 
260–266.
Chen, X., Zhang, M., Zhou, C., Kallenbach, N. R., and Ren, 
D. (2011). Control of bacterial persister cells by trp/
arg-containing antimicrobial peptides. Appl. Environ. 
Microbiol. 77, 4878–4885.
Desgranges, S., Le Prieult, F., Daly, A., Lydon, J., Brennan, 
M., Rai, D. K., et al. (2011). In vitro activities against 
cystic fibrosis pathogens of synthetic host defence pro-
peptides processed by neutrophil elastase. Antimicrob. 
Agents Chemother. 55, 2487–2489.
Desgranges, S., Ruddle, C. C., Burke, L. P., McFadden, T. 
M., O’Brien, J. E., Fitzgerald-Hughes, D., et al. (2012). 
β-Lactam-host defence peptide conjugates as antibi-
otic prodrug candidates targeting resistant bacteria. 
RSC Adv. 2, 2480–2492.
Eckert, R., He, J., Yarbrough, D. K., Qi, F., Anderson, M. H., 
and Shi, W. (2006). Targeted killing of Streptococcus 
mutans by a pheromone-guided “Smart” antimi-
crobial peptide. Antimicrob. Agents Chemother. 50, 
3651–3657.
Finlay, B. B., and Hancock, R. E. W. (2004). Can innate 
immunity be enhanced to treat microbial infections? 
Nat. Rev. Microbiol. 2, 497–504.
Fjell, C. D., Hiss, J. A., Hancock, R. E. W., and Schneider, 
G. (2012). Designing antimicrobial peptides: form 
follows function. Nat. Rev. Drug Discov. 11, 37–51.
Franzman, M. R., Burnell, K. K., Dehkordi-Vakil, F. H., 
Guthmiller, J. M., Dawson, D. V., and Brogden, K. A. 
(2009). Targeted antimicrobial activity of a specific 
IgG–SMAP28 conjugate against Porphyromonas gin-
givalis in a mixed culture. Int. J. Antimicrob. Agents 
33, 14–20.
Giacometti, A., Cirioni, O., Del Prete, M. S., Barchiesi, 
F., Fortuna, M., Drenaggi, D., et al. (2000). In vitro 
activities of membrane-active peptides alone and in 
combination with clinically used antimicrobial agents 
against Stenotrophomonas maltophilia. Antimicrob. 
Agents Chemother. 44, 1716–1719.
Hancock, R. E., Nijnik, A., and Philpott, D. J. (2012). 
Modulating immunity as a therapy for bacterial infec-
tions. Nat. Rev. Microbiol. 10, 243–254.
Hancock, R. E. W. (2001). Cationic peptides: effectors in 
innate immunity and novel antimicrobials. Lancet 
Infect. Dis. 1, 156–164.
Hancock, R. E. W., and Sahl, H.-G. (2006). 
Antimicrobial and host-defense peptides as new 
anti-infective therapeutic strategies. Nat. Biotechnol. 
24, 1551–1557.
Harris, J. M., and Chess, R. B. (2003). Effect of pegyla-
tion on pharmaceuticals. Nat. Rev. Drug Discov. 2, 
214–221.
Imura, Y., Nishida, M., and Matsuzaki, K. (2007). Action 
mechanism of PEGylated magainin 2 analogue pep-
tide. Biochim. Biophys. Acta 1768, 2578–2585.
Kennedy, D. A., Vembu, N., Fronczek, F. R., and 
Devocelle, M. (2011). Synthesis of mutual azo 
prodrugs of anti-inflammatory agents and peptides 
facilitated by α-aminoisobutyric acid. J. Org. Chem. 
76, 9641–9647.
Lehrer, R. I. (2004). “Overview: antimicrobial 
peptides, as seen from a rearview mirror,” in 
Mammalian Host Defense Peptides, eds D. A. 
Devine and R. E. W. Hancock (Cambridge: 
Cambridge University Press), 5–8.
Li, L., He, J., Eckert, R., Yarbrough, D., Lux, R., Anderson, 
M., et al. (2010). Design and characterization of an 
acid-activated antimicrobial peptide. Chem. Biol. 
Drug Des. 75, 127–132.
Li, Y. (2011). Recombinant production of antimicrobial 
peptides in Escherichia coli: a review. Protein Expr. 
Purif. 80, 260–267.
Mader, J. S., and Hoskin, D. W. (2006). Cationic anti-
microbial peptides as novel cytotoxic agents for 
cancer treatment. Expert Opin. Investig. Drugs 15, 
933–946.
McClanahan, J. R., Peyyala, R., Mahajan, R., Montelaro, 
R. C., Novak, K. F., and Puleo, D. A. (2011). Bioactivity 
of WLBU2 peptide antibiotic in combination with 
bioerodible polymer. Int. J. Antimicrob. Agents 38, 
530–533.
Mygind, P. H., Fischer, R. L., Schnorr, K. M., Hansen, 
M. T., Sönksen, C. P., Ludvigsen, S., et al. (2005). 
Plectasin is a peptide antibiotic with therapeutic 
potential from a saprophytic fungus. Nature 437, 
975–980.
Papo, N., and Shai, Y. (2005). Host defense peptides as 
new weapons in cancer treatment. Cell. Mol. Life Sci. 
62, 784–790.
Pauletti, G. M., Gangwar, S., Siahaan, T. J., Aubé, J., and 
Borchardt, R. T. (1997). Improvement of oral peptide 
bioavailability: peptidomimetics and prodrug strate-
gies. Adv. Drug Deliv. Rev. 27, 235–256.
Peschel, A., and Sahl, H.-G. (2006). The co-evolution of 
host cationic antimicrobial peptides and microbial 
resistance. Nat. Rev. Microbiol. 4, 529–536.
Peschen, D., Li, H.-P., Fischer, R., Kreuzaler, F., and Liao, 
Y.-C. (2004). Fusion proteins comprising a Fusarium-
specific antibody linked to antifungal peptides protect 
plants against a fungal pathogen. Nat. Biotechnol. 22, 
732–738.
Pokrovskaya, V., and Baasov, T. (2010). Dual-acting 
hybrid antibiotics: a promising strategy to combat 
bacterial resistance. Expert Opin. Drug Discov. 5, 
883–902.
Qiu, X.-Q., Wang, H., Lu, X.-F., Zhang, J., Li, S.-F., Cheng, 
G., et al. (2003). An engineered multidomain bac-
tericidal peptide as a model for targeted antibiot-
ics against specific bacteria. Nat. Biotechnol. 21, 
1480–1485.
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., 
Oh, D., Järvinen, T., et al. (2008). Prodrugs: design 
and clinical applications. Nat. Rev. Drug Discov. 7, 
255–270.
Stella, V. J. (2004). Prodrugs as therapeutics. Expert Opin. 
Ther. Patents 14, 277–280.
Szynol, A., de Haard, J. J. W., Veerman, E. C., de Soet, J. 
J., and van Nieuw Amerongen, A. V. (2006). Design 
of a peptibody consisting of the antimicrobial 
peptide dhvar5 and a llama variable heavy-chain 
antibody fragment. Chem. Biol. Drug Des. 67, 
425–431.
Urbán, P., Valle-Delgado, J. J., Moles, E., Marques, J., Díez, 
C., and Fernàndez-Busquets, X. (2012). Nanotools 
www.frontiersin.org October 2012 | Volume 3 | Article 309 | 3
Devocelle Targeted antimicrobial peptides
Zasloff, M. (2002). Antimicrobial peptides of multicel-
lular organisms. Nature 415, 389–395.
Received: 23 August 2012; accepted: 17 September 2012; 
published online: 05 October 2012.
Citation: Devocelle M (2012) Targeted antimicro-
bial peptides. Front. Immun. 3:309. doi: 10.3389/
fimmu.2012.00309
for the delivery of antimicrobial peptides. Curr. Drug 
Targets 13, 1158–1172.
Yeaman, M. R., and Yount, N. Y. (2007). Unifying themes 
in host defence effector polypeptides. Nat. Rev. 
Microbiol. 5, 727–740.
Yount, N. Y., and Yeaman, M. R. (2012). Emerging themes 
and therapeutic prospects for anti-infective peptides. 
Annu. Rev. Pharmacol. Toxicol. 52, 337–360.
This article was submitted to Frontiers in Molecular Innate 
Immunity, a specialty of Frontiers in Immunology.
Copyright © 2012 Devocelle. This is an open-access arti-
cle distributed under the terms of the Creative Commons 
Attribution License, which permits use, distribution and 
reproduction in other forums, provided the original authors 
and source are credited and subject to any copyright notices 
concerning any third-party graphics etc.
Frontiers in Immunology | Molecular Innate Immunity  October 2012 | Volume 3 | Article 309 | 4
Devocelle Targeted antimicrobial peptides
